Evaluating the Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market’s Growth Prospects from 2024 to 2033
Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!
How is the Growth Rate of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Estimated for 2024-2033?
The market for drugs targeting methicillin-resistant staphylococcus aureus (MRSA) has significantly expanded in the past few years. The market value is projected to increase from $2.26 billion in 2023 to $2.38 billion in 2024, with a compound annual growth rate (CAGR) of 5.2%. Factors contributing to the growth during the historic period include worries over antibiotic resistance, infections acquired in hospital settings, surgical procedures, a worldwide rise in MRSA cases, and high death rates.
The market size for drugs combating methicillin-resistant staphylococcus aureus (mrsa) is projected to witness substantial growth in the coming years. The market value is expected to reach $2.9 billion by 2028, expanding at a compound annual growth rate (CAGR) of 5.1%. The anticipated expansion during this forecasted timeframe can be ascribed to ongoing issues with antibiotic resistance, advancements in diagnosing mrsa, worldwide healthcare-associated infections, surgical prevention measures, and a surge in community-contracted mrsa instances. Forecast period trends comprise the study of immunomodulators, strategic collaborations for medication development, personalized therapies derived from strain characteristics, emphasis on pediatric-targeted formulas, and international health initiatives to battle antibiotic resistance.
Claim Your Free Sample of the Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Report Today!
https://www.thebusinessresearchcompany.com/sample.aspx?id=10859&type=smp
What Key Drivers Are Propelling the methicillin-resistant staphylococcus aureus (mrsa) drugs Market’s Growth?
The growth of the methicillin-resistant Staphylococcus aureus (MRSA) drugs market is forecasted to accelerate in response to the escalating prevalence of MRSA infections. MRSA is a type of Staphylococcus bacteria that has developed resistance to various antibiotics regularly used to treat typical staph infections. To effectively manage MRSA infections, drugs capable of combating and curbing the proliferation of MRSA bacteria in humans and animals are necessary. For example, the Centers for Disease Control and Prevention, a US health agency operating under the Department of Health and Human Services, reported in November 2022 that the incidences of hospital-acquired MRSA infections grew by 14% between 2020 and 2021. Moreover, the Statens Serum Institute, a Denmark-based research institute focused on MRSA, noted in a December 2022 report that the count of community-acquired infections with documented associations with a hospital or nursing sector in the preceding six months stood at 181 in 2021, a rise from 159 recorded in 2020. Consequently, the mounting prevalence of MRSA infections is propelling the MRSA drugs market’s expansion.
What Are the Distinct Segments of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market?
1) By Drug Class: Lipopeptides, Oxazolidinones, Cephalosporin, Tetracycline, Folate Antagonist, Lipoglycopeptide, Other Drug Classes
2) By Indication: Skin Infections, Bone and Joint Infections, Bacteremia, Animal Infections
3) By MRSA Type: Hospital-Acquired (HA-MRSA), Community-Acquired (CA-MRSA)
4) By Route of Administration: Oral Administration, Parenteral Administration
5) By End User: Hospitals and Clinics, Research and Academic Institutes, Other End-Users
Which New Trends Are Making Waves in the Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market?
In the Methicillin-Resistant Staphylococcus aureus (MRSA) drug market, product innovation is emerging as a dominant trend. To keep a hold on their market positions, the key players in the Methicillin-Resistant Staphylococcus aureus (MRSA) drug market are focusing on bringing innovative products to the table. For instance, Melinta Therapeutics LLC, a biopharmaceutical company from the US, received the FDA’s green light in March 2021 for their product Kimyrsa (oritavancin), which is to be used in the treatment of adult patients suffering from acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of specified gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA). Kimyrsa, the first oritavancin one-hour infusion product made from a single 1,200 mg vial, is compatible with both 0.9% sodium chloride injection (NS) and 5% dextrose in sterile water (D5W). This drug works by inhibiting transpeptidation, stalling transglycosylation, and disrupting the cell membrane’s integrity.
Order Now for Fast Delivery of Your Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Report!
Which Regions Are Significant to the Growth of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market?
North America was the largest region in the global methicillin-resistant staphylococcus aureus drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the methicillin-resistant staphylococcus aureus (mrsa) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the methicillin-resistant staphylococcus aureus (mrsa) drugs market, its market share, and analyzes key competitors along with their market positions.
The Table Of Content For The Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Include
1. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Executive Summary
2. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Segments
3. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Size And Template Market Growth Rate
4. Key Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Trends
5. Major Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Drivers
……
25. Key Mergers And Acquisitions In The Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market
26. Top Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Companies
27. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Opportunities And Strategies
28. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Conclusions And Recommendations
29. Appendix
Discover Related Reports by The Business Research Company:
Plasticizers Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/plasticizers-global-market-report
Polymer Biomaterial Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/polymer-biomaterial-global-market-report
Paper, Plastics, Rubber, Wood And Textile Global Market Report 2024
Learn More About The Business Research Company
The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
